Skip to content

Released Feb 17, 2022, after the close

10-K filed Mar 8, 2022, 67 days after period end · 0001162194-22-000021

Q4 2021 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$38.27Mderived−14.2% vs Q4 2020+34.2% vs Q3 2021
Net Income-$9.43MderivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$11,259,000N/M
Operating Cash Flowderived-$7,002,000N/M
Free Cash Flowderived-$7,465,000N/M
Margins · derived
Operating margin-29.4%+8.5 pt vs Q4 2020
Net margin-24.6%+15.8 pt vs Q4 2020

What the release said

The release

Same quarter

MetricQ4 2021derived from reported figuresQ4 2020Q4 2019Q4 2018
Revenue$38.27M$44.61M$32.44M$32.33M
Net Income-$9.43M-$18.03M-$12.69M-$14.78M
EPS Diluted—-$0.24-$0.18-$0.36

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR